Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
How to watch the World Rowing Championships 2023 online for free
IShowSpeed 'forgives' Man City fan who attacked him at FA Cup final but Internet says he 'deserved it'
Netflix's aim with gaming is to have a game for everyone
How to Get Nicki Minaj in Warzone
Is Warzone 2 Season 6 the Final MW2 Season?
The ‘Yield Curve’ Is Improving. These Types of Stocks Should Benefit.
Valorant Patch 7.09 Agent Tier List
Apple sends invites for iPhone event on Sept. 12